Conviction in the face of affliction: a case series of Jehovah’s Witnesses with myeloid malignancies

The treatment of acute lymphoblastic leukemia in Jehovah's Witnesses and patients who cannot accept blood products

“…Patients were given supportive care with B12, folate, erythropoiesis stimulating agents, thrombopoietin receptor agonists, anti-fibrinolytics, and granulocyte colony stimulating factors. The use of the aforementioned medications has been well documented during induction chemotherapy for acute leukemia [ 6 , [9] , [10] , [11] , [12] , [13] , [14] ]. NCCN guidelines for JW with acute myeloid leukemia also support the use of such agents, and though no such guidelines formally exist for ALL, these supportive measures should be discussed with and offered to all Jehovah's witnesses who will undergo myelosuppressive chemotherapy.…”